Lisinopril
Zestril / Prinivil
Lisinopril (Zestril / Prinivil) is a longevity & bioregulators research compound. ACE inhibitor — blocks conversion of angiotensin I to II. Also blocks bradykinin breakdown, which is where the cough comes from.
Lisinopril quick facts
| Reported research dose | 5–40mg daily |
| Route | Oral |
| Frequency | 1x |
| Half-life | ~12 hours |
| Forms | Oral |
| Evidence level | Decades of human outcome data |
Effective and cheap, but the dry cough affects roughly 10% and is the usual reason people switch to an ARB. ⚠️ Angioedema is rare but a genuine emergency. Contraindicated in pregnancy. Watch potassium, especially alongside a potassium supplement.
How Lisinopril works
ACE inhibitor — blocks conversion of angiotensin I to II. Also blocks bradykinin breakdown, which is where the cough comes from.
Proposed benefits
Researched for mitochondrial and cellular-energy support, tissue-specific bioregulation and healthy-aging pathways.
Where to get Lisinopril
Buy Lisinopril at AlgoRx →The evidence for Lisinopril
Graded by what exists behind each claim.
✅ Clinically validated
- Approved with decades of major trial data. Landmark evidence includes GISSI-3 and ATLAS in heart failure and post-MI, showing mortality reduction, plus its established role in slowing diabetic nephropathy.
- The renal protection is not explained by blood pressure lowering alone, which is why ACE inhibitors are first-line in diabetic kidney disease specifically.
📊 Correlative data
- One of the most-prescribed drugs in the world. The dry cough is the signature effect — it affects a substantial minority, is not dose-dependent, and is the single most common reason for switching to an ARB.
- Angioedema is rare and can be life-threatening, and occurs at a higher rate in Black patients — a well-documented difference that affects prescribing choice.
🧪 Theoretical / extrapolated
- Inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II — so less vasoconstriction, less aldosterone, less sodium retention.
- ACE also degrades bradykinin, and inhibiting it lets bradykinin accumulate. That single fact explains both the cough and the angioedema, and it is why ARBs — which block the receptor instead of the enzyme — avoid them.
- Preferential dilation of the efferent arteriole lowers intraglomerular pressure, which is the mechanism behind the kidney protection and also why creatinine rises slightly on starting it.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Lisinopril actually does
Angiotensin-converting enzyme has a second name, and that second name is this whole page: kininase II. It is one zinc-dependent dipeptidyl carboxypeptidase with two substrates. Working on angiotensin I it clips off the C-terminal dipeptide His-Leu and produces angiotensin II. Working on bradykinin it clips dipeptides off and destroys it. One active site, two jobs, and lisinopril blocks both at once. Every good thing and every bad thing on this page falls out of that single fact.
The chemistry that separates lisinopril from the rest of the class. It is the lysine analog of enalaprilat, and it carries a free carboxylate that coordinates the active-site zinc directly. That means it is active as swallowed. Enalapril, ramipril and perindopril are ethyl esters that a hepatic esterase has to cleave before anything happens. Lisinopril needs no such step, and the label states the consequence flatly: it does not undergo metabolism and is excreted unchanged entirely in the urine US Food and Drug Administration 2017. No cytochrome, no prodrug conversion, no first-pass activation. The kidney sets the exposure and nothing else does.
The bradykinin arm, which is the interesting half. Bradykinin you fail to destroy accumulates, and bradykinin acting on endothelial B2 receptors releases nitric oxide and prostacyclin — part of the blood-pressure effect is therefore not the angiotensin arm at all. The same accumulation sensitizes airway sensory C-fibers, which is the cough, and in a small minority drives plasma extravasation in the lips, tongue and larynx, which is the angioedema. An ARB blocks the AT1 receptor and leaves the enzyme running, so bradykinin is never raised. That is exactly why switching to losartan or telmisartan fixes an ACE-inhibitor cough and why it is not a “tolerance” issue.
And there is a second bradykinin-clearing enzyme, which is why angioedema is not a dose problem. Adam 2002 measured plasma aminopeptidase P in 39 hypertensive patients who had had angioedema on an ACE inhibitor and 39 who had not. Activity was significantly lower in the angioedema group (p = 0.003). Read that as a reserve system: if ACE is blocked and your backup peptidase runs slow, bradykinin has nowhere to go. It explains why angioedema arrives unpredictably, sometimes after years of uneventful use, and why lowering the dose is not a strategy.
Downstream of the angiotensin arm, less angiotensin II means less aldosterone, so less sodium held and less potassium dumped — hyperkalemia. And angiotensin II is what constricts the efferent glomerular arteriole, so removing it drops intraglomerular pressure. Creatinine rises a little as a direct result. That rise is the drug doing its job, not failing.
Cell, rodent, human — and where it stops
Step one, the enzyme. There is no cell-culture step worth reporting for a drug whose target was characterized before it existed; the relevant chemistry is that the free carboxylate binds active-site zinc without activation, which is what makes this the ACE inhibitor that does not need a liver US Food and Drug Administration 2017.
Step two, human pharmacokinetics, and it is unusually clean. Beermann 1988 reports oral bioavailability of 25 ± 4% in healthy volunteers, an accumulation half-life of 12.6 hours, a terminal serum half-life of about 40 hours, steady state after two once-daily doses, elimination entirely renal by glomerular filtration with tubular secretion and reabsorption, and no pharmacokinetic interaction with furosemide. van Schaik 1988 then did the experiment that matters clinically: in hypertensive patients the effective half-life doubled in mild renal impairment and tripled in severe renal failure, and accumulation correlated tightly with creatinine clearance. Same drug, three different exposures, decided entirely by the kidney.
Step three, the outcome trials — and one of them missed its primary endpoint. GISSI-3 gave lisinopril 2.5–10 mg daily for six weeks starting within 24 hours of an acute myocardial infarction. Zuanetti 1997 analyzed the 2,790 diabetic patients inside the 18,131 with data available: six-week mortality was 8.7% versus 12.4%, odds ratio 0.68 (95% CI 0.53–0.86), which is 37 ± 12 lives saved per 1,000 diabetics treated; at six months, 12.9% versus 16.1%, OR 0.77 (0.62–0.95). The benefit was significantly larger in diabetics than in non-diabetics (p < 0.025). That is as hard as cardiovascular evidence gets.
ATLAS is the one people quote loosely. Packer 1999 randomized 3,164 patients with NYHA class II–IV heart failure and an ejection fraction of 30% or less to low-dose lisinopril (2.5–5.0 mg) or high-dose (32.5–35 mg) for 39 to 58 months. Mortality — the primary endpoint — did not reach significance: 8% lower on the high dose, p = 0.128. What did reach it was the composite of death or hospitalization for any reason, 12% lower (p = 0.002), and hospitalization for heart failure specifically, 24% fewer (p = 0.002). Dizziness and renal insufficiency were more common on the high dose, and discontinuation rates were similar. The honest reading is that dose buys fewer hospital admissions, not demonstrably fewer deaths.
The obstacle, and it is a population obstacle rather than a species one. Every number above came from a sick person — day-one post-infarction, or an ejection fraction under 30%, or diabetic with an infarct. None of it was generated in a healthy adult taking 10 mg for a blood pressure of 138/86 or for a longevity thesis, and the absolute benefit of any intervention scales with baseline risk. The second obstacle is mechanistic: no trial in this drug's history has measured bradykinin. The peptide that explains the cough, the angioedema and an unknown share of the blood-pressure drop has never been a study endpoint, so the mechanism half of this page rests on inference and the outcome half rests on mortality counts.
Lisinopril pharmacokinetics — how much of it actually gets in
Route: oral, once daily, and the number that surprises people is how little gets in. Absorption is approximately 25%, with large intersubject variability of 6% to 60% US Food and Drug Administration 2017; Beermann 1988 measured 25 ± 4%. Three quarters of the tablet never reaches the circulation and it does not matter, because the quarter that does is potent and long-acting.
What degrades it: nothing. This is the rare drug with no metabolic step at all. The label states it does not undergo metabolism and is excreted unchanged entirely in the urine US Food and Drug Administration 2017, cleared by glomerular filtration together with tubular secretion and reabsorption Beermann 1988. There is no cytochrome P450 route, so grapefruit, azole antifungals, ritonavir and the rest of the CYP3A4 list do nothing to it. Every interaction that matters for lisinopril is pharmacodynamic — potassium, NSAIDs, aliskiren, lithium — not metabolic.
Two half-lives, and confusing them is the common error. The accumulation half-life is 12.6 hours, which is the one the label reports as an effective half-life of 12 hours and the one that governs once-daily dosing and steady state after about two doses. Underneath it there is a terminal phase of roughly 40 hours Beermann 1988, which reflects slow dissociation from tissue-bound ACE rather than a second compartment of free drug. Practical consequence: the antihypertensive effect outlasts the plasma curve, and a missed dose is far less dramatic than the 12-hour figure implies.
The kidney is the dose. Half-life doubles in mild renal impairment and triples in severe renal failure, and accumulation tracks creatinine clearance van Schaik 1988; the label sets no adjustment above a creatinine clearance of 30 mL/min and a lower starting dose below it US Food and Drug Administration 2017. There is no injectable lisinopril — the intravenous ACE inhibitor is enalaprilat, the active metabolite of a different molecule — so nothing here is bypassable by injection, and 25% oral absorption is the whole delivery story.
What would have to be true, and how you would know it was not
Four predictions. The third is the safety one and the fourth cuts against the drug.
1. Potassium and creatinine both rise, once, and then stop. Draw a Comprehensive Metabolic Panel (CMP) at baseline and again at 1–2 weeks. The mechanism — less aldosterone, less efferent arteriolar tone — predicts a small rise in potassium and a small rise in creatinine that plateaus. The label reports hyperkalemia in 2.2% of hypertensive and 4.8% of heart failure patients US Food and Drug Administration 2017. What is not predicted is a creatinine that keeps climbing at week four or a potassium above 5.5 mmol/L; when that happens the cause is almost always the drug plus something else — an NSAID, a potassium supplement, a potassium-based salt substitute, spironolactone or trimethoprim.
2. Cystatin C is the better second number and almost nobody orders it. Creatinine on an ACE inhibitor is ambiguous: it rises because filtration pressure fell, which is the intended effect, and it also rises if filtration genuinely failed, which is not. Cystatin C with eGFR does not depend on muscle mass and moves on a different basis, so drawing both at baseline and at 8–12 weeks separates the two readings. Prediction: creatinine up modestly, cystatin C roughly flat. If both climb together, the assumption that this is benign hemodynamics is wrong.
3. Albumin in the urine should fall, and faster than the blood pressure explains. A routine Urinalysis with an albumin-to-creatinine ratio at baseline and 12 weeks. The efferent mechanism predicts a fall in albuminuria that is partly independent of the systolic number, which is the actual argument for using this class in kidney disease. If albuminuria only moves in proportion to blood pressure, the class-specific claim is not being demonstrated in you.
4. The prediction that cuts against it: the cough will not settle, and reducing the dose will not fix it. Bradykinin accumulation is a consequence of enzyme blockade, not of concentration above a threshold, so a cough at week four should still be there at week twelve and should still be there at half the dose. The label's placebo-subtracted excess is 2.5% in hypertension US Food and Drug Administration 2017. If somebody's cough reliably disappears on a dose reduction, that cough was probably not this drug — and if it disappears on an ARB, it was.
What nobody has tested yet
Nobody has ever screened aminopeptidase P before prescribing. Adam 2002 showed that people who develop ACE-inhibitor angioedema carry significantly lower plasma aminopeptidase P activity than people who do not (p = 0.003), in 39 versus 39 patients. That is a single plasma enzyme assay on a single tube of blood, and in the twenty-plus years since, no one has run it prospectively as a pre-prescription screen. A prospective cohort measuring baseline aminopeptidase P and then counting angioedema events would either turn an unpredictable, occasionally fatal reaction into a predictable one or kill the hypothesis. It is the single most valuable unrun experiment attached to one of the most-prescribed drugs on earth.
Nobody has measured bradykinin in a person on an ACE inhibitor and correlated it with the blood-pressure fall. If a meaningful share of the antihypertensive effect is bradykinin-mediated rather than angiotensin-mediated, then people who cough should on average be better responders — the cough would be a marker of target engagement rather than a nuisance. That is a testable, slightly heretical prediction and the data to check it does not exist.
Nobody has tested whether the 40-hour terminal phase supports alternate-day dosing. The tissue-bound compartment Beermann 1988 is why the effect outlasts the plasma curve. A crossover study of 10 mg daily against 20 mg every other day, with 24-hour ambulatory blood pressure and a potassium check on each arm, would settle a question that matters for anyone whose limiting problem is a trough-hour side effect rather than efficacy.
Lisinopril — its own safety story, not its class's
This drug carries a boxed warning and it is about pregnancy. Drugs acting directly on the renin-angiotensin system can cause injury and death to a developing fetus, and the label's instruction is to discontinue as soon as pregnancy is detected US Food and Drug Administration 2017. That is not a class caution to skim; it is the reason this is not a drug to share, keep loose, or continue on autopilot in anyone who could become pregnant.
Angioedema is the emergency, and the label's own wording is specific. Angioedema of the face, extremities, lips, tongue, glottis and larynx, including some fatal reactions, has occurred US Food and Drug Administration 2017. Two facts change how to think about it. It occurs at a higher rate in Black than in non-Black patients — the label says so explicitly, and it is a genuine prescribing consideration. And it is not time-limited: because it depends on backup-peptidase reserve Adam 2002 rather than on cumulative dose, it can appear after years of uneventful use. Airway swelling on this drug is an emergency-department problem, not a wait-and-see problem, and the drug is then contraindicated for life — the label lists prior angioedema, hereditary or idiopathic, as a contraindication.
Hyperkalemia is the quiet one, and it is a stacking problem. The label reports it in 2.2% of hypertension trials and 4.8% of heart failure trials US Food and Drug Administration 2017, and heart failure is higher because those patients are also on spironolactone and have worse renal function. The compounding list is longer than most people realize: potassium supplements, potassium-containing salt substitutes, spironolactone and eplerenone, NSAIDs, trimethoprim, and heavy supplemental magnesium-potassium blends sold for cramps. A single CMP catches all of it.
Two contraindications people miss. Do not combine with aliskiren in anyone with diabetes — that is an outright contraindication on the label, not a caution US Food and Drug Administration 2017. And dual blockade generally (an ACE inhibitor plus an ARB) buys more hyperkalemia and more renal impairment without a mortality return.
The dose-versus-harm trade is measured, not guessed. ATLAS ran high dose against low dose head to head for up to 58 months and reported more dizziness and more renal insufficiency on the high dose, with similar discontinuation rates, for a mortality difference that did not reach significance (p = 0.128) and a 24% reduction in heart failure hospitalization that did Packer 1999. So higher doses are defensible in heart failure and much harder to defend in an otherwise well person chasing a slightly lower number.
Finally, renal artery stenosis and volume depletion. The same efferent-arteriole mechanism that protects a diabetic kidney is the mechanism that collapses filtration in a kidney fed by a stenosed artery, or in someone dehydrated, on a diuretic, or on an NSAID. Acute renal failure on this class is nearly always one of those three situations, and it is reversible if it is caught — which is what the two-week CMP is for.
Sources read for this page
- Beermann B. Pharmacokinetics of lisinopril.. Am J Med 1988 · PMID 2844083
- van Schaik BA, Geyskes GG, van der Wouw PA, van Rooij HH, Porsius AJ. Pharmacokinetics of lisinopril in hypertensive patients with normal and impaired renal function.. Eur J Clin Pharmacol 1988 · PMID 2834209
- Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.. Circulation 1999 · PMID 10587334
- Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study.. Circulation 1997 · PMID 9416888
- Adam A, Cugno M, Molinaro G. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.. Lancet 2002 · PMID 12086766
- US Food and Drug Administration. ZESTRIL (lisinopril) tablets, for oral use - full prescribing information.. FDA approved labeling, revision 2017
Lisinopril — safety, from the human record
Not a prediction. This one has been studied in people. What follows is drawn from the human record — trials, labels and pharmacovigilance — rather than from what the mechanism implies. Where the way it is used here differs from what was studied, the card says so. How evidence is graded here →
What the mechanism predicts
Derived from the molecule, not a trial.
- One axis, two places to block it. ACE inhibitors (lisinopril) stop angiotensin I becoming angiotensin II; ARBs (losartan, telmisartan) leave the conversion alone and block the receptor. The predicted consequences follow from the axis rather than from either drug: less vasoconstriction, less aldosterone, less sodium retention — and therefore first-dose hypotension, and reduced glomerular filtration pressure that shows up as a creatinine rise.
- The cough belongs to the ACE inhibitors only, and it is mechanism rather than allergy: ACE also degrades bradykinin, so blocking it lets bradykinin accumulate. That is why switching to an ARB resolves it, and why the cough is not a reason to avoid the whole axis.
- Telmisartan carries a second mechanism the others do not — partial PPAR-gamma agonism, the receptor the glitazones hit. That is the reason it gets chosen in performance circles, and it is also the reason its effects on lipids, insulin sensitivity and fluid balance are not simply 'losartan with better numbers'.
What has actually been reported
- A creatinine rise of up to about 30% after starting is expected hemodynamics, not injury, and is the single most common reason these get stopped unnecessarily. A larger or continuing rise is a different matter and needs review.
- Hyperkalemia is the dose-limiting effect for most people, and it compounds with potassium supplements, potassium-sparing diuretics, NSAIDs and reduced kidney function.
- Dry cough on ACE inhibitors is common and can begin weeks in. Angioedema is rare and is an emergency — it involves the airway, it can appear after months of uneventful use, and it does not reliably recur on rechallenge, which is why people talk themselves back onto it.
- Losartan is uricosuric — it lowers urate. That is a genuine advantage for anyone whose diuretic or diet pushes uric acid up, and it is a real difference between ARBs rather than marketing.
How to reduce the risk
Same mechanism as the prediction.
- Start low and take the first dose at night. Most first-dose hypotension is a one-off, and being horizontal for it is free.
- Book the two-week bloods when you start, not when you remember. Potassium and creatinine are the two things that go wrong, and neither produces a symptom until it is well advanced.
- Know the sick-day rule: hold these during significant vomiting, diarrhea or dehydration, and restart when you are eating and drinking normally.
- If the cough starts, ask about switching to an ARB rather than abandoning the axis — same benefit, no bradykinin.
What it does to your bloodwork
A fact about the assay.
- Electrolytes and creatinine 1–2 weeks after starting or after any dose change — that is where hyperkalemia and a filtration drop both show up, and both are silent.
- Repeat renal function during anything that causes volume depletion: a stomach bug, a hot race, a fasting protocol. The 'sick day rule' exists because dehydration plus RAAS blockade plus an NSAID is the classic acute kidney injury.
- Losartan lowers uric acid, so a urate result on it is not a clean baseline.
What it overlaps with
- NSAIDs blunt the antihypertensive effect and add to the renal risk. Potassium-sparing diuretics and potassium supplements add to the hyperkalemia risk. Neither is an interaction claim — both are the same mechanism arriving from two directions.
Don't run this if
- Pregnancy or trying to conceive. Both classes are fetotoxic in the second and third trimesters. This is not a caution, it is a contraindication.
- Bilateral renal artery stenosis, or a single functioning kidney with stenosis — the drop in filtration pressure is the whole problem there.
- A prior episode of angioedema on an ACE inhibitor.
- Do not combine an ACE inhibitor with an ARB. The combination increased harm without benefit in trials and there is no version of the longevity argument that survives that finding.
The honest unknown
- Whether any of the geroprotective signal survives in normotensive people. Every outcome trial behind these drugs enrolled people with hypertension, heart failure, diabetic kidney disease or established cardiovascular disease. Taking a blood-pressure drug for longevity with a normal blood pressure is an extrapolation, and the honest position is that it is untested rather than disproven.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Lisinopril — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Lisinopril moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Potassium and creatinine are the two that matter, and a CMP has both. ACE inhibitors and ARBs raise potassium by reducing aldosterone, and they cause a small expected rise in creatinine when started — a rise under about 30% is hemodynamic and is not kidney damage.
What to do: Baseline, then again 1–2 weeks after starting or after any dose increase. That second draw is the one people skip and it is the one that matters. - Cystatin C with eGFR — ◆ worth watching
A better read of kidney filtration than creatinine if you carry a lot of muscle — creatinine-based eGFR reads falsely low on a muscular person and turns a normal kidney into a scary number.
What to do: Worth one measurement if creatinine-based eGFR looks borderline and you train hard. - Uric Acid — ↓ expected to fall
Losartan specifically is uricosuric — it lowers uric acid, which is a genuine and under-used advantage if gout is in the picture. This is NOT a class effect; the other ARBs do not do it.
What to do: Relevant only if you have gout or a high baseline urate.
Beta-blockers are a different mechanism to the two above and carry their own specific caution: never stop one abruptly. Rebound tachycardia and hypertension are well documented. They also blunt the adrenaline response, which masks the early warning signs of hypoglycemia and flattens the training heart-rate response.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Lisinopril in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Lisinopril
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Chronic low-grade inflammation is the process most of these target |
| ApoB (Apolipoprotein B) | Counts the particles that actually cause plaque, unlike LDL-C |
| HbA1c (Hemoglobin A1c) | Glycation, which is the other half of the ageing story |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney — the two organs that clear everything you take |
| Complete Blood Count (CBC) with Differential | The cheapest broad screen there is |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Lisinopril — frequently asked questions
What is Lisinopril?
Lisinopril (Zestril / Prinivil) is a longevity & bioregulators research compound. ACE inhibitor — blocks conversion of angiotensin I to II. Also blocks bradykinin breakdown, which is where the cough comes from.
Is the full Lisinopril protocol on this page?
The reported research dose is on this page, along with how Lisinopril works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Lisinopril?
Lisinopril has an approximate half-life of ~12 hours, which is part of what determines how often it's dosed.
What's the evidence behind Lisinopril?
Current evidence level: Decades of human outcome data. Lisinopril is offered for research purposes only and is not an approved medicine.
What Lisinopril is used for
Lisinopril appears under 2 goals in the goal router.
Related Longevity & Bioregulators compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.